Serum Estradiol‐Binding Profiles in Postmenopausal Women Undergoing Three Common Estrogen Replacement Therapies: Associations With Sex Hormone‐Binding Globulin, Estradiol, and Estrone Levels*

@article{Nachtigall2000SerumEP,
  title={Serum Estradiol‐Binding Profiles in Postmenopausal Women Undergoing Three Common Estrogen Replacement Therapies: Associations With Sex Hormone‐Binding Globulin, Estradiol, and Estrone Levels*},
  author={Lila E. Nachtigall and Uma Raju and S. Banerjee and Liang Wan and Mortimer Levitz},
  journal={Menopause},
  year={2000},
  volume={7},
  pages={243–250}
}
Objective: To compare the effects of three commonly prescribed estrogen replacement therapies—oral conjugated equine estrogens (CEE; n = 37), oral micronized estradiol (ME; n = 25), and transdermal estradiol (TE; n = 24)—on the binding characteristics of plasma estradiol as related to the concentrations of blood sex hormone‐binding globulin (SHBG), estradiol, and estrone. Design: Menopausal volunteers, opting for estrogen replacement therapy, gave blood at 0, 2, and 4 months. SHBG was assayed… Expand
The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women
TLDR
These data provide a reference point for the serum hormone response toHT and demonstrate that the response of serum estrogens is similar for ET and EPT, which suggest a larger response to HT in women with low endogenous levels. Expand
Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy
TLDR
More studies are needed to support the findings for HRT users and to further investigate estrogen levels in relation to estrogen receptor-specific breast cancer and other histological and molecular subtypes. Expand
Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy
TLDR
More studies are needed to support the findings for HRT users and to further investigate estrogen levels in relation to estrogen receptor-specific breast cancer and other histological and molecular subtypes. Expand
Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis
TLDR
Users of systemic E2-containing HRT preparations have plasma E2 and FSH levels comparable to premenopausal women, and NOWAC questionnaires provide valid information on current HRT use and menopausal status among Norwegian women. Expand
Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
TLDR
The contraceptive patch had an effect comparable to the OC on several key androgenic markers and has significant potential as a therapeutic agent for disorders of androgen excess. Expand
Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women’s Health Initiative Observational Study
TLDR
The data suggest that postmenopausal BMI is associated with increased circulating levels of parent estrogens and reduced methylation of catechol estrogen metabolites, the estrogen metabolism patterns that have previously been associated with higher breast cancer risk. Expand
Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis.
TLDR
Women with ESRD should receive approximately 50% of the dose typically prescribed to women without E SRD, compared with normal renal function in order to determine equivalent dosing. Expand
Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal
  • M. L'hermite
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2017
TLDR
MHT continuously combining oral micronized progesterone with transdermal estradiol can presently be considered as the optimal MHT, which is not only safer than custom-compounded bioidentical hormones but also than oral conventional MHT and has the best breast profile. Expand
Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma.
TLDR
Overall, no association was found between any use of HRT and the risk of invasive EOC in women participating in a population-based, case-control study conducted in the Delaware Valley from 1994 to 1998 and the results did not suggest any consistent pattern of altered risk for EOC. Expand
Effect of microdose transdermal 17&bgr;-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial
TLDR
Transdermal microdose E2 was similarly effective as raloxifene in preventing bone loss at the lumbar spine and both treatments were well tolerated, with no clinically significant effect on endometrium or breast density. Expand
...
1
2
3
4
5
...